A live webcast of the panel discussion will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the panel will be available for 30 days ...

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter Passage Bio ( (PASG)) has provided an update. On May 19, 2026, Passage Bio, Inc. held ...

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (PASG) (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of ...

PHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases ...

Passage Bio has raised its second megaround of 2019. Months after breaking cover with a $115.5 million series A, the James Wilson-founded gene therapy startup has reeled in another $110 million to ...

Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatment "We are proud to announce initial clinical data from our upliFT ...

James M. Wilson, MD, PhD, director of the Gene Therapy Program at the University of Pennsylvania, and a co-founder of Passage Bio. Passage Bio, a developer of gene therapies for rare monogenic CNS ...

Gene therapy developers have been ringing out 2020 with a series of announcements about new manufacturing facilities, or at least production agreements with CDMOs. This month, Thermo Fisher said it ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The new board chairwoman is a former GlaxoSmithKline ...

Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...